Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 7.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 462,867 shares of the company’s stock after buying an additional 33,123 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.23% of Taysha Gene Therapies worth $930,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Creative Planning purchased a new stake in shares of Taysha Gene Therapies in the third quarter valued at $28,000. Principal Financial Group Inc. purchased a new position in Taysha Gene Therapies in the 2nd quarter valued at about $48,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Taysha Gene Therapies during the third quarter worth about $85,000. Finally, Scientech Research LLC acquired a new position in shares of Taysha Gene Therapies in the second quarter valued at approximately $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on TSHA. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Price Performance

TSHA opened at $2.03 on Wednesday. The company has a 50 day moving average of $2.15 and a two-hundred day moving average of $2.33. Taysha Gene Therapies, Inc. has a 52-week low of $1.19 and a 52-week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market cap of $416.03 million, a P/E ratio of 3.22 and a beta of 0.79.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.